BERKELEY, Calif.--(BUSINESS WIRE)--Caribou Biosciences, Inc., a leading company in CRISPR-Cas genome engineering, today announced that the United States Patent and Trademark Office (USPTO) has granted Vilnius University a CRISPR-Cas9 genome editing patent. Caribou has rights to this intellectual property in multiple fields of use, including exclusive access in the research tools field. Caribou gained these rights as part of its worldwide cross-license agreement with DuPont Company, to which Vilnius University exclusively licensed this intellectual property.
The Vilnius patent covers methods of modifying DNA using a recombinant CRISPR-Cas9 complex assembled in vitro and is complementary to the exclusive license that Caribou already has from the University of California and the University of Vienna to the foundational CRISPR-Cas9 intellectual property.
“We are delighted to see this important patent grant to Vilnius University,“ said Dr. Rachel Haurwitz, President and CEO of Caribou. “These rights are an important addition to the extensive and leading IP portfolio Caribou is building, and will help to facilitate our future technology advancements and product development in gene editing.”
About Caribou Biosciences
Caribou is a leading company in CRISPR genome engineering founded by pioneers of CRISPR-Cas9 biology based on research carried out in the Doudna Laboratory at the University of California, Berkeley. Caribou’s tools and technologies provide transformative capabilities to therapeutic development, agricultural biotechnology, industrial biotechnology, and basic and applied biological research.
Caribou offers licenses to its CRISPR-Cas9 foundational IP in multiple fields including research tools, internal research use, diagnostics, and industrial biotechnology. Interested companies can contact Caribou at firstname.lastname@example.org.
For more information about Caribou, visit www.cariboubio.com and follow the Company @CaribouBio. “Caribou Biosciences” and the Caribou logo are registered trademarks of Caribou Biosciences, Inc.